This document is a USPTO patent application (US20260083839A1) filed on September 22, 2023, which was published on March 26, 2026. It describes a method for treating non-small cell lung cancer (NSCLC) in patients who have previously received treatment with an immune checkpoint inhibitor. The proposed treatment involves the administration of dostarlimab or a biosimilar thereof.

As this is a patent application, it does not impose immediate compliance obligations on regulated entities. However, it signifies potential future developments in cancer treatment therapies and intellectual property within the pharmaceutical sector. Compliance officers in the pharmaceutical and biotechnology industries should be aware of such filings as they may indicate emerging treatment modalities and competitive landscapes.